Stocklytics Platform
Asset logo for symbol IONS
Ionis Pharmaceuticals
IONS52
$47.82arrow_drop_up1.03%$0.49
Asset logo for symbol IONS
IONS52

$47.82

arrow_drop_up1.03%

AI Deep-Learning Forecast (IONS)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Ionis Pharmaceuticals (IONS) Stocklytics Forecast

The stock price of Ionis Pharmaceuticals Inc (IONS) has shown potential for growth in recent years, and many analysts are predicting a positive outlook for the future. With advancements in the pharmaceutical industry and the company's focus on innovative therapies, there is a strong likelihood that the stock price will continue to rise. According to AI and machine learning predictions, Ionis Pharmaceuticals Inc's stock price is expected to experience an upward trend in the coming years.

By 2023, Ionis Pharmaceuticals Inc's stock price is forecasted to reach new heights. Analysts have set a price target for the company, indicating their confidence in its growth potential. The current analyst ratings also reflect a favorable view of the stock, further supporting the notion that IONS is a good buy. Investors looking for a promising investment in the pharmaceutical sector should consider Ionis Pharmaceuticals Inc, as it has the potential for significant returns.

add Ionis Pharmaceuticals  to watchlist

Keep an eye on Ionis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the analyst price prediction for Ionis Pharmaceuticals (IONS) stock?

Analysts have set a target price of $59 for Ionis Pharmaceuticals (IONS), based on forecasts from 26 analysts. The predicted price range extends from a high of $82 to a low of $28. This represents a potential increase of up to 71.48% and a decrease of -41.45% from the current price of $47.82. These forecasts are as of 2023 May 04.

help
What are the analyst ratings for Ionis Pharmaceuticals (IONS) stock?

The analyst ratings for Ionis Pharmaceuticals (IONS) are distributed as follows: 5 analysts recommend buying, 8 have a neutral stance, and 2 suggest selling. The prevailing sentiment among the total of 15 analysts leans towards a neutral rating. These ratings indicate the general sentiment among the analysts covering Ionis Pharmaceuticals .

help
What is the AI price prediction for Ionis Pharmaceuticals (IONS) stock?

At present, there is no AI or machine-learning-based price prediction available for Ionis Pharmaceuticals (IONS) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level